In connection with the interim report for the second quarter 2024, Kancera AB (publ) today provides a general operational update concerning its clinical development program and reports that: the phase IIa part in the KANDOVA study has been initiated...
Read MoreThe period in brief – financial summary for the second quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 9,7 million (SEK 16,5 million). Operating loss for the quarter amounted to...
Read MoreKancera AB (publ) announces that the results from the FRACTAL study will be presented at the European Society of Cardiology (ESC) annual conference on September 2, 2024.
Read MoreKancera AB (publ) today reports that the first part, phase Ib, has been successfully completed in the ongoing KANDOVA study, a combined phase Ib/IIa study of Kancera’s candidate drug KAND567 in ovarian cancer in combination with carboplatin. The objective...
Read MoreThe period in brief – financial summary for the first quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million) R&D expenses amounted to SEK 11,4 million (SEK 15,2 million) Operating loss for the quarter amounted to...
Read More